Timothy W. Mullett named chair of the Commission on Cancer of the American College of Surgeons

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Cardiothoracic surgeon Timothy W. Mullett, medical director of the Markey Cancer Center Affiliate Network, was named chair of the Commission on Cancer of the American College of Surgeons.

Mullett has been serving as the chair-elect of the CoC for the past year.

Mullett is a surgical oncologist who specializes in the treatment of lung cancer. Although he began his career at the University of Kentucky as a cardiothoracic surgeon treating heart issues, he soon shifted his professional focus to treating lung cancer. Today, he is a co-leader and principal investigator of the Kentucky LEADS Collaborative to improve lung cancer survival.

In addition to his work in lung cancer research, Mullett serves as the chair of UK’s cancer committee and the medical director of the Markey Cancer Center Research Network, a collaborative network that conducts high-priority trials, including therapeutic oncology trials and interventional and non-interventional studies for community centers.

In his role as chair, Mullett will serve as the spokesperson for oncology issues addressed by the organization, identify priorities for the CoC and National Cancer Database.

YOU MAY BE INTERESTED IN

Physician-scientists by day, a funk-loving musical troupe by night. You may have seen The CheckPoints—a 13 member cover band with a three-piece brass section and Jim Allison on harmonica—movin’, groovin’, and gettin’ down as a mainstay closing act at ASCO, AACR, or the Society for Immunotherapy of Cancer annual meetings. 
At the 2026 Annual Meeting of the American Society of Clinical Oncology in Chicago, results from the phase III HARMONi-6 trial were presented at the plenary session and published simultaneously in The Lancet. The HARMONi-6 trial tested a novel bispecific antibody that engages PD-1 and VEGF (ivonescimab), given with platinum-doublet chemotherapy to patients with previously untreated advanced squamous non-small cell lung cancer. 
In 2026, more than 900 million people are estimated to be regularly using generative artificial intelligence—computer systems capable of creating human-like text, images, audio, video, and other original content. AI is becoming integrated into nearly every aspect of daily life. Health care is no exception. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login